Haematology 2018

INV-assessed PFS by chemotherapy backbone (10 September 2016 cut-off)

1.0

1.0

1.0

1.0

All patients

Bendamustine

CHOP

CVP

0.8

0.8

0.8

0.8

0.6

0.6

0.6

0.6

0.4

0.4

0.4

0.4

R-chemo G-chemo

R-chemo G-chemo

R-chemo G-chemo

R-chemo G-chemo

0.2

0.2

0.2

0.2

Survival Probability

Survival Probability

Survival Probability

Survival Probability

0

0

0

0

12

24 36 48 60

12

24 36 48 60

12

24 36 48 60

12

24 36 48 60

0

0

0

0

Time (months)

Time (months)

Time (months)

Time (months)

No. at risk

No. at risk

No. at risk

No. at risk

601 601

505 535

438 478

267 291

77 85

341 345

285 305

250 276

163 179

52 61

203 196

179 174

152 153

84 84

20 18

57 60

41 56

36 49

20 28

5 6

1

1

HR, 0.68 (95% CI: 0.54, 0.87); p=0.0016

HR, 0.63 (95% CI: 0.46, 0.88); p=0.0062

HR, 0.72 (95% CI: 0.48, 1.10); p=0.1266

HR, 0.79 (95% CI: 0.42, 1.47); p=0.4560 3-year PFS : 71.3% for G-CVP vs 64.2% for R-CVP

3-year PFS : 81.5% for G-Chemo vs 75.0% for R-chemo

3-year PFS : 84.1% for G-B vs 76.4% for R-B

3-year PFS : 80.6% for G-CHOP vs 75.6% for R-CHOP

• PFS was superior with G-chemo relative to R-chemo with consistent effects across chemo regimens • Study not designed or powered to compare differences between R-chemo and G-chemo within chemo groups

Hiddemann W, et al. ICML 2017 (Abstract 107)